Gene · 28234
Papers2,854
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,854
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A mechanistic study revealing that SLCO1B3 promotes gastric cancer development and metastasis through MAP1S expression downregulation. | BMC Cancer | 2026 | 41906106 | PubTator, text mining | PubMed |
| Human Organoids and Organ-on-Chip for Biotoxin Assessment: Applications, Best Practices, and a Translational Roadmap. | Toxins (Basel) | 2026 | 41893572 | PubTator, text mining | PubMed |
| Structural basis for prostaglandin and drug transport via SLCO2A1. | Nat Commun | 2026 | 41862483 | PubTator, text mining | PubMed |
| A virtual screening and molecular dynamics approach in search of novel antibiotic chemotypes. | PLoS One | 2026 | 41860821 | PubTator, text mining | PubMed |
| Impact of Pharmacokinetic Gene Polymorphisms on Statin-Induced Myotoxicity in Thai Patients Treated With Simvastatin. | Clin Transl Sci | 2026 | 41860236 | PubTator, text mining | PubMed |
| Post-translational regulation of organic anion transporting polypeptide 1B3 transport function by lysine acetylation and lysine deacetylase 6 inhibition. | Drug Metab Dispos | 2026 | 41791215 | PubTator, text mining | PubMed |
| Gd-EOB-DTPA MRI radiomics-clinical nomogram for preoperatively predicting dual-positive Ki-67/MVI status in hepatocellular carcinoma: A retrospective study. | Medicine (Baltimore) | 2026 | 41790668 | PubTator, text mining | PubMed |
NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts. | Cancer Chemother Pharmacol | 2026 | 41790137 | PubTator, text mining | PubMed |
| Personalized pharmacokinetic-pharmacodynamic guided therapy via an induced pluripotent stem cell-derived multi-organoid platform in NF1-mutant breast cancer. | Signal Transduct Target Ther | 2026 | 41781386 | PubTator, text mining | PubMed |
| The value of gadobenate dimeglumine-enhanced MRI quantification in predicting aggressiveness and prognosis of typical intrahepatic mass-forming cholangiocarcinoma: a multicenter retrospective study. | Insights Imaging | 2026 | 41774304 | PubTator, text mining | PubMed |
| Remdesivir in COVID-19: pros and cons. | Front Pharmacol | 2026 | 41769697 | PubTator, text mining | PubMed |
| Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers. | J Antimicrob Chemother | 2026 | 41766350 | PubTator, text mining | PubMed |
| Indoxyl Sulfate in the Gut-Kidney Axis: Pathophysiology and Clinical Significance in CKD-Associated Colorectal Cancer. | Toxins (Basel) | 2026 | 41745738 | PubTator, text mining | PubMed |
| Constitutional indocyanine green excretion defect in a Chinese patient without underlying liver disease: case report and mechanistic insights. | Front Med (Lausanne) | 2026 | 41737405 | PubTator, text mining | PubMed |
| Multimodal imaging techniques in Yttrium-90 radioembolization for hepatocellular carcinoma: a modality-oriented clinical review. | Front Oncol | 2026 | 41710661 | PubTator, text mining | PubMed |
| Expert Consensus on the Diagnosis and Management of Inherited Hyperbilirubinemia (2025). | J Clin Transl Hepatol | 2026 | 41659992 | PubTator, text mining | PubMed |
| The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications. | Clin Transl Sci | 2026 | 41635062 | PubTator, text mining | PubMed |
| Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters-In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling. | Clin Transl Sci | 2026 | 41630535 | PubTator, text mining | PubMed |
| A conserved salt bridge network stabilizes the hepatic organic anion transporters OATP1B1 and OATP1B3. | J Biol Chem | 2026 | 41617032 | PubTator, text mining | PubMed |
| Machine learning models for drug-drug interaction prediction from computational discovery to clinical application. | NPJ Digit Med | 2026 | 41611854 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28234/papers?page=2